N/A N=24 Euflexxa for the Treatment of Osteoarthritis
Osteo Arthritis Knee
Primary: Change in Hyaluronate Concentration — 0.29568 mg/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=211 A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
Follicular Lymphoma · Small Lymphocytic Lymphoma · Marginal Zone Lymphoma
Primary: Event Free Survival — 47.7; 49.5 Percentage of Participants — p=0.26
Phase 2 N=189 Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction
Postoperative Delirium · Postoperative Cognitive Dysfunction
Primary: Number of Adverse Events (AEs) of Grade II or Higher Per Patient — 1; 2 events per participant — p=0.025
Phase 2 N=27 Trial of Indomethacin in Chronic Pancreatitis
Chronic Pancreatitis
Primary: Change in Prostaglandin E2 (PGE2) Concentrations — -457.7; -840.4 pg/ml
Phase 2 N=70 Intravenous(IV) vs. Erector Spinae Plane Blocks in Cardiac Surgery
Erector Spinae Plane Block · Pain Control · Post-Operative Pain, Chronic
Primary: Quantitate the Amount of Opioid Medication Required to Provide Pain Relief-Cumulative First 48 Hours — 80.2; 54.9 Morphine Milligram Equivalents
Phase 2 N=261 A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease
Chronic Kidney Disease
Primary: Change From Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in 10-hour Urine After 20 Weeks of Trial Treatment — -0.210; -0.190; -0.217; 0.018…
Phase 2 N=25 Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma
ISS Stage I Plasma Cell Myeloma · ISS Stage II Plasma Cell Myeloma · ISS Stage III Plasma Cell Myeloma
Primary: Number of Participants With Adverse Events — 8 Participants
Phase 4 N=46 Wet Time for a Foam Hand Sanitizer
Hand Hygiene Effectiveness
Primary: Foam Sanitizer Wet Time Duration — 35.41 time in seconds
Phase 2 N=154 Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
Glabellar Frown Lines
Primary: Duration of Effect Described by Kaplan-Meier Analysis — 183; 148; 149 Days — p=0.0109
Phase 2 N=323 Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving a 20% Improvement in American College of Rheumatology (ACR) Criteria at Week 8 — 47; 61; 69; 73 Percentage of participants
N/A N=28 Sex Differences in Risk for Alcohol Abuse
Alcohol Abuse
Primary: Brain Activation During Response Inhibition (BARI) - Alcohol Infusion — 1.83; 2.41 BOLD activation
N/A N=129 Axonics SacRal NeuromodulaTIon System for Urinary Urgency Incontinence TreatmeNt
Urinary Incontinence, Urge
Primary: Proportion of Responders — 113 Participants
N/A N=17 Resurgence as Choice: Basic and Clinical Studies
Problem Behavior · Self-injury · Communication
Primary: Number of Participants Showing Resurgence as Predicted by the Quantitative Model -- Highest Response Rate — 1; 5 Participants
N/A N=74 Piloting +Connection is Medicine / The Healing Spirits Program
Mental Health Issue · Depressive Symptoms · Anxiety
Primary: Group Differences in Mean Scores for Caregiver and Youth General Distress Over Time as Assessed by the Kessler Psychological Distress Scale — 8.56; 8.69; 6.52; 8.0 score…
Phase 1 N=13 A Study to Assess Safety and Immunogenicity of Conserved Mosaic HIV-1 Vaccines
HIV
Primary: Assessement of Safety — 0; 0 Participants